Literature DB >> 34218000

Synthesis, bioevaluation and docking studies of new imidamide derivatives as nitric oxide synthase inhibitors.

Fabio Arias1, Francisco Franco-Montalban1, Miguel Romero2, M Dora Carrión3, M Encarnación Camacho4.   

Abstract

In search of new Nitric Oxide Synthase (NOS) inhibitor agents, two isosteric series of derivatives with an imidamide scaffold (one of them with a hydroxyl group and the other with a carbonyl one) were synthesized and evaluated on inducible (iNOS) and neuronal (nNOS) isoforms. These compounds have been designed by combining a kynurenamine framework with an amidine moiety in order to improve selectivity for the inducible isoform. In general, the in vitro inhibitory assays exhibited better inhibition values on the iNOS isoform, being the N-(3-(2-amino-5-methoxyphenyl)-3-hydroxypropyl)-4-(trifluoromethyl)benzimidamide 4i the most active inhibitor with the highest iNOS selectivity, without inhibiting eNOS. Docking studies on the two most active compounds suggest a different binding mode on both isozymes, supporting the experimentally observed selectivity towards the inducible isoform. Physicochemical in silico studies suggest that these compounds possess good drug-likeness properties.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Drug design; Imidamides; Inhibitors; Nitric Oxide Synthase; Synthesis

Mesh:

Substances:

Year:  2021        PMID: 34218000     DOI: 10.1016/j.bmc.2021.116294

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  1 in total

1.  New dibenzocyclooctadiene lignans from Kadsura induta with their anti-inflammatory activity.

Authors:  Bui Huu Tai; Pham Hai Yen; Nguyen Huy Hoang; Phan Thi Thanh Huong; Nguyen Viet Dung; Bui Van Thanh; Nguyen The Cuong; Ngo Anh Bang; Nguyen Xuan Nhiem; Phan Van Kiem
Journal:  RSC Adv       Date:  2022-09-07       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.